MedPath

STEPS-EA trial

Phase 1
Conditions
Strictures after esophageal atresia repair
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Registration Number
CTIS2023-504905-36-00
Lead Sponsor
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
110
Inclusion Criteria

Children with EA type C who underwent primary anastomotic surgery within the first days of life, Age =3 months at the time of the 3rd dilatation, In need of a 3rd dilatation, Written informed consent by both parents or legal representatives, if applicable

Exclusion Criteria

Age <3 months, Known inability from previous dilatations to use an endoscope with a size of 5.8 mm, No parental written informed consent

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: The primary objective is to find out whether intralesional steroid injections (ISI) in children with esophageal atresia (EA) can prevent refractory strictures from developing and consequently can reduce the total number of dilatations needed within 28 days interval.;Secondary Objective: To compare the level of dysphagia, To compare the efficacy of the effect of dilatation with ISI on the luminal esophageal diameter and the stricture length, To evaluate a possible influence of co-medication on stricture formation, To analyze the possible systemic effects of ISI, To analyze the costs-effectiveness of the intervention between the two groups.;Primary end point(s): The total number of dilatations within 28 days interval needed per patient during the study period, i.e. from the day of the 3rd dilatation until 6 months later.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath